A fly in the ointment: reassessing mitotane’s role in the treatment of adrenocortical carcinoma
Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin
Decoded advanced breast cancer ‘signatures’ could help predict benefit from estrogen-lowering therapy
Memorandum of Understanding signed between Gentris® Corporation and Shanghai Institutes of Preventative Medicine
Fox Chase Cancer Center study suggests not all patients will pay for genetic testing
Series C financing raises US$12.5 million towards personalized medicine company, AssureRx Health, Inc.
Predicting response to statins by pharmacogenetic testing
The importance of gene–gene interactions in statin efficacy
The role of genome-wide association studies in confirming the importance of potential therapeutic targets
Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study
Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study
The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis
HLA and pharmacogenetics of drug hypersensitivity
NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice
Acknowledgements